Deal of the Week: Melinta/The Medicines Co.’s Antibiotics

Deal of the Week: Melinta/The Medicines Co.’s Antibiotics

by | Dec 1, 2017 8:08 pm | Pharmaceuticals

As part of a previously announced restructuring plan, The Medicines Company (NASDAQ: MDCO) is selling its infectious disease business unit in order to double-down on its promising drug candidate, inclisiran. The drug is currently in Phase 3 development, and completion is expected in the second half of 2019. That’s a long way away, and MDCO needs “sufficient cash and liquidity” to reach the goal line. That’s why, on November 29, the company announced an agreement to sell its infectious disease business unit, including three marketed antibiotics, Vabomere, Orbactiv® and Minocin IV. Melinta Therapeutics, Inc. (NASDAQ: MLNT), the buyer, will pay $540 million, as well as... Read More »